Solid Biosciences to Participate at The Citizens Life Sciences Conference
Rhea-AI Summary
Solid Biosciences (Nasdaq: SLDB), a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced its upcoming participation in The Citizens Life Sciences Conference.
The company's President and CEO, Bo Cumbo, will engage in a fireside chat scheduled for Wednesday, May 7, at 12:30 pm ET. Interested parties can access the presentation through a live webcast available on the Events page of the company's Investors section website.
Key Details:
- Event: The Citizens Life Sciences Conference
- Format: Fireside Chat
- Date & Time: May 7, 12:30 pm ET
- Replay Availability: 30-day archive access
Institutional investors seeking management meetings during the conference are advised to contact their Citizens representative.
Positive
- CEO participation in a major life sciences conference indicates strong institutional visibility
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, SLDB gained 8.52%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
CHARLESTOWN, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, announced that Bo Cumbo, President and CEO, will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7, at 12:30 pm ET.
A live webcast of the fireside chat will be available on the Events page of the Investors section of the Company website or by clicking here. The webcast replay will be archived for 30 days on the Events page.
Institutional investors interested in meeting with management during the conference may reach out to their Citizens representative.
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy (Duchenne), Friedreich’s ataxia (FA), catecholaminergic polymorphic ventricular tachycardia (CPVT), TNNT2-mediated dilated cardiomyopathy, BAG3-mediated dilated cardiomyopathy, and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
FAQ
When is Solid Biosciences (SLDB) presenting at The Citizens Life Sciences Conference 2025?
How can investors watch Solid Biosciences' (SLDB) Citizens Conference presentation?
What type of medicines is Solid Biosciences (SLDB) developing in 2025?
How can institutional investors meet with Solid Biosciences (SLDB) management at the Citizens Conference?
What is the format of Solid Biosciences' (SLDB) presentation at the Citizens Life Sciences Conference?
